

Meeting Overview & Objective (12:30 – 4:30 CST / 4 hours)

The MPT field is complex involving those working on contraceptives and anti-infectives, including HIV and other STIs; product developers; funders; social-behavioral researchers; and others. In 2009, the Initiative for MPTs (IMPT) was launched as a product-neutral learning network and serves as a platform for identifying fieldwide priority action areas and driving innovation through insights, collaboration, awareness-raising, and advocacy.

The **objective of this meeting is to convene stakeholders working in the areas of combining anti-infectives and contraceptives into single product entities to advance the MPT field in order to facilitate information exchange and learnings between groups who may not convene regularly but would benefit from increased interaction.** While numerous researchers are working on contraceptives and sexually transmitted infectives (STI) preventatives, including HIV, much of this research continues to proceed along parallel tracks. This interactive half-day workshop will be focused on highlighting both scientific challenges and breakthroughs in the STI and MPT fields where researchers, product developers, funders, and supporting agencies and other interested parties can learn from each other. This meeting will also provide a forum to assess specific needs to advance the MPT field.

Meeting Agenda (4 hours)

12:30 – 12:45 CST (15 min)

Welcome and Introductions

12:45 – 2:45 CST (2 hours)

MPT Pipeline Overview: Products that are currently in the pipeline as well as products that are no longer being funded.

- **NIH portfolio: NIAID, NICHD, NIMH** (James Cummins & Jon Glock)
- **USAID portfolio** (Shannon Allen)
- **QA**

Lessons Learned from Bridging Contraceptive R&D to MPTs: Panel Discussion

Invited panelists:

- Brandi Howard (Premier Research)
- Kevin Whaley (ZabBio)
- Marc Baum (OCIS)
- Lisa Haddad (Population Council)
- Mary Weitzel (Yaso Therapeutics)

Discussion with panelists and presenters

2:45 – 3:00 CST (15 min)

Coffee/snack/bio break

3:00 – 3:35 CST (35 min)

IMPT Strategic Action Areas and Breakout sessions (in-person and virtual options):

1. Investor engagement: What do investors and other potential partners need & want to know?
2. Expanded understanding of SBR considerations among underrepresented groups and those with underlying conditions in MPT research
3. Dosing and platform issues
4. Market considerations to ensure successful MPT commercialization and uptake
5. Clinical Trial considerations specific for MPTs: trial prep, models, and bioequivalence

3:35 – 4:10 CST (35 min)

Re-convene from Breakouts and Discussion

4:10 – 4:20 CST (10 min)

CAMI Health Led Discussion: Proposed STI Prevention Database

4:20 – 4:30 CST (10 min)

Wrap-up & Adjourn